uploads/2019/02/anatomical-2261006_1280.jpg

Analysts’ Recommendations for AstraZeneca and Eli Lilly

By

Updated

Stock price movements

On February 22, AstraZeneca (AZN) closed at $40.94, 1.26% higher than its previous closing price, 25.24% higher than its 52-week low of $32.69, and 2.00% below its 52-week high of $41.78. Its market capitalization was $103.74 billion, and its trailing-12-month and forward PE ratios were 48.16x and 19.51x, respectively.

AstraZeneca released its fourth-quarter results on February 14. Its stock rose 11.92% from $36.58 on February 13 to $40.94 on February 22. It beat analysts’ revenue estimate by $90 million and their EPS estimate by $0.10.

Article continues below advertisement

On February 22, Eli Lilly (LLY) closed at $124, 1.04% higher than its previous closing price, 66.42% higher than its 52-week low of $74.51, and 0.19% below its 52-week high of $123.76. Its market capitalization was $127.07 billion, and its trailing-12-month and forward PE ratios were 39.58x and 19.36x, respectively.

Eli Lilly released its fourth-quarter results on February 6. Its stock rose 5.86% from $119.78 on February 5 to $124 on February 22. Although the company’s revenue of $6.43 billion was above analysts’ estimate by $140 million, its EPS of $1.33 missed their estimate by $0.01. Eli Lilly has lower trailing and forward PE ratios than AstraZeneca.

Analysts’ recommendations and target price

Most analysts recommend “buy” for AstraZeneca and Eli Lilly. Of the five analysts covering AstraZeneca, three recommend “strong buy,” one recommends “buy,” and one recommends “hold.” Their 12-month target price is $44.08, 7.67% higher than its February 22 closing price. Their highest and the lowest price estimates for the stock are $48 and $40, respectively.

Of the 16 analysts covering Eli Lilly, two recommend “strong buy,” five recommend “buy,” and nine recommend “hold.” Their 12-month target price is $120.07, 3.17% below its February 22 closing price. Their highest and the lowest price estimates for the stock are $143 and $93, respectively. Next, we’ll look at AstraZeneca’s and Eli Lilly’s revenue growth.

Advertisement

More From Market Realist